Objective To explore the association of the gene amplification of c⁃Met with the clinical and pathological features in non⁃small cell lung cancer( NSCLC) patients, and the correlation with other driver genes such as EGFR, K⁃Ras and EML4⁃ALK. Methods The c⁃Met gene amplification status was detected by fluorescence in situ hybridization( FISH) in the 108 cases of NSCLC specimens. The expression of c⁃Met and EML4⁃ALK fusion gene were detected by real⁃time quantitative PCR( qRT⁃PCR) . Mutations of EGFR and K⁃Ras were detected using PCR⁃based direct sequencing. The correlation of the gene amplification of c⁃Met with clinicopath⁃ologic features and the other driver genes such as EGFR, K⁃Ras, and EML4⁃ALK was analyzed. Results ( 1) Among 108 NSCLC pa⁃tients, c⁃Met gene amplification was observed in two cases(1�85%). The proportions of c⁃Met gene amplification in smokers and non⁃smokers were 2�94% and 1�35%, respectively. The c⁃Met gene amplification was detected in 1�23% adenocarcinoma patients but none in squamous carcinoma patients. There was separately one patient harboring c⁃Met gene amplification in stageⅠand stageⅢ( 2�50%;5�00%).(2) The mutation rates of the EGFR and K⁃Ras gene were 42�59% and 5�56%. The positive rate of EML4⁃ALK fusion gene was 12�04%. Conclusion The proportion of the gene amplification of c⁃Met detected by FISH was consistent with c⁃Met expression levels analysed by qRT⁃PCR. The four driver genes were almost mutually exclusive. And no correlation was found between c⁃Met gene amplification and various clinicopathologic features such as age, sex, smoking status, histological types, and clinical stages.%目的：探讨非小细胞肺癌（ NSCLC）中肝细胞生长因子受体（ c⁃Met）基因扩增与临床病理特征的关系以及分析c⁃Met与EGFR、K⁃Ras和EML4⁃ALK驱动基因的相关性。方法采用荧光原位杂交技术（ FISH）检测108例NSCLC患者的c⁃Met基因扩增情况，实时荧光定量PCR（ qRT⁃PCR）检测EML4⁃ALK融合基因及c⁃Met基因表达量，聚合酶链扩增反应（ PCR）及直接测序法检测EGFR和K⁃Ras基因突变情况，并分析c⁃Met基因与临床病理特征的关系及其与EGFR、K⁃Ras和EML4⁃ALK驱动基因的关系。结果 NSCLC 中 c⁃Met 基因扩增率为1�85％，其在吸烟和非吸烟患者中扩增率分别为2�94％和1�35％；腺癌c⁃Met基因扩增率为1�23％，鳞癌未发现c⁃Met基因扩增；仅Ⅰ期和Ⅲ期中分别有1例c⁃Met基因扩增。 NSCLC中EGFR、K⁃Ras基因突变及EML4⁃ALK融合基因的阳性率分别为42�59％、5�56％和12�04％。结论 FISH法对c⁃Met基因扩增检出率与qRT⁃PCR检测的c⁃Met基因表达水平基本一致；c⁃Met基因扩增与EGFR、K⁃Ras突变及EML4⁃ALK融合基因之间几乎是不共存的，c⁃Met扩增与NSCLC患者年龄、性别、吸烟状态、肿瘤组织类型及临床分期无关。
展开▼
